Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ARQT 
Arcutis Biotherapeutics Inc (ARQT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ARQT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21.86
1 Year Target Price $21.86
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 116.99% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.07B USD | Price to earnings Ratio - | 1Y Target Price 21.86 |
Price to earnings Ratio - | 1Y Target Price 21.86 | ||
Volume (30-day avg) 7 | Beta 1.94 | 52 Weeks Range 8.03 - 18.15 | Updated Date 09/13/2025 |
52 Weeks Range 8.03 - 18.15 | Updated Date 09/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -35.4% | Operating Margin (TTM) -17.93% |
Management Effectiveness
Return on Assets (TTM) -13.46% | Return on Equity (TTM) -57.33% |
Valuation
Trailing PE - | Forward PE 217.39 | Enterprise Value 1992498798 | Price to Sales(TTM) 7.87 |
Enterprise Value 1992498798 | Price to Sales(TTM) 7.87 | ||
Enterprise Value to Revenue 7.56 | Enterprise Value to EBITDA -2.04 | Shares Outstanding 119905000 | Shares Floating 85611027 |
Shares Outstanding 119905000 | Shares Floating 85611027 | ||
Percent Insiders 1.9 | Percent Institutions 109.89 |
Upturn AI SWOT
Arcutis Biotherapeutics Inc
Company Overview
History and Background
Arcutis Biotherapeutics, Inc. was founded in 2016. It is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. Significant milestones include the FDA approval and commercial launch of ZORYVE (roflumilast) topical cream.
Core Business Areas
- Medical Dermatology: Focuses on developing and commercializing therapies for common dermatological conditions like plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia areata.
Leadership and Structure
Todd Simpson is the CEO. The company has a typical biopharmaceutical organizational structure, with departments focusing on research, development, commercialization, and operations.
Top Products and Market Share
Key Offerings
- ZORYVE (roflumilast) topical cream: A topical PDE4 inhibitor approved for the treatment of plaque psoriasis in individuals 12 years and older. While specific market share data is still evolving, ZORYVE is competing with other topical corticosteroids, vitamin D analogs, and other PDE4 inhibitors. Competitors include LEO Pharma (Enstilar), Bristol Myers Squibb (Otezla), and numerous generic topical steroids. Arcutis reported preliminary Q1 2024 ZORYVE net product revenue of $52.0 million.
- ROFLUMILAST FOAM: A topical roflumilast formulation in development for seborrheic dermatitis and atopic dermatitis. Still awaiting potential FDA approval and market launch, so no current market share or revenue. Competitors will include topical corticosteroids, antifungal agents, and calcineurin inhibitors. Key competitors will be LEO Pharma, Galderma, and other dermatology companies with established brands in these indications.
Market Dynamics
Industry Overview
The medical dermatology market is large and growing, driven by an aging population, increased awareness of skin conditions, and the development of novel therapies.
Positioning
Arcutis is positioned as an innovative company focused on developing novel topical therapies for inflammatory skin diseases, targeting unmet needs with potentially safer and more effective treatments.
Total Addressable Market (TAM)
The global dermatology market is projected to reach hundreds of billions of dollars. Arcutis is focused on capturing a significant portion of the topical treatment market for psoriasis, atopic dermatitis, and seborrheic dermatitis, positioning them to address a multi-billion dollar TAM.
Upturn SWOT Analysis
Strengths
- Novel PDE4 inhibitor technology
- FDA-approved product (ZORYVE)
- Strong clinical data
- Experienced management team
Weaknesses
- Limited commercial history
- Reliance on a single approved product
- High operating expenses
- Dependence on successful clinical trials for pipeline products
Opportunities
- Expansion into new indications (e.g., atopic dermatitis, seborrheic dermatitis)
- Partnerships and collaborations
- Geographic expansion
- Positive clinical trial results
Threats
- Competition from established players
- Regulatory hurdles
- Pricing and reimbursement pressures
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- BMY
- LEO.CO
- SNY
Competitive Landscape
Arcutis has the advantage of a novel mechanism of action and potentially improved safety profile for ZORYVE. Disadvantages include limited commercial experience and the need to compete with established players with greater resources and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is marked by the company's transition from a research-focused entity to a commercial-stage organization with the launch of ZORYVE.
Future Projections: Future growth is dependent on the successful commercialization of ZORYVE and the approval and launch of pipeline products. Analyst estimates suggest significant revenue growth in the coming years, but also continued operating losses.
Recent Initiatives: Recent strategic initiatives include expanding the ZORYVE sales force, advancing clinical trials for roflumilast foam, and exploring potential partnerships.
Summary
Arcutis Biotherapeutics is a developing company with a promising FDA approved product in ZORYVE. The success of ZORYVE will determine the company's ability to expand indications and gain market share in a competitive landscape. The company has a solid product and faces standard financial concerns that occur with new releases and is on the right track. However, they must be aware of competitors in a very saturated market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Arcutis Biotherapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is based on available estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcutis Biotherapeutics Inc
Exchange NASDAQ | Headquaters Westlake Village, CA, United States | ||
IPO Launch date 2020-01-31 | President, CEO & Director Mr. Todd Franklin Watanabe M.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 342 | Website https://www.arcutis.com |
Full time employees 342 | Website https://www.arcutis.com | ||
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.